Finding your way in ADC bioanalytics
‘Finding your way in ADC bioanalytics’ provides a short overview of the different bioanalytical assay types and technologies that can be used, each with its own characteristics, requirements and challenges.
Antibody-drug conjugates (ADCs) combine potent payloads with a highly selective antibody to guide the payload to its target. Although the first ADC was approved as a treatment in 2000, the number of ADCs currently on the market remains limited and ~13 are currently used in mostly oncological applications. However, due to improvements in the structural design of mainly the linker between antibody and payload, the number of new-generation ADCs that are currently being developed is now rapidly growing.
‘Finding your way in ADC bioanalytics’ is part of the Bioanalysis Zone Spotlight on ADC bioanalytics. Click here to view the full feature.
In association with:
